Kao Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KAOOY research report →
Price Chart
About the company
Kao Corporation develops and sells hygiene living care, health beauty care, life care, cosmetics, and chemical products in Japan. It offers fabric, kitchen, home, and sanitary care products; facial, body, hair, and oral care, hair styling and color, salon, in-bathroom health care, and warming products; and self-selection cosmetics, as well as provides cosmetics counselling services. It also provides oleo chemicals, such as oleochemicals, fat and oil derivatives, surfactants, and fragrances; water-reducing admixtures for concrete, casting sand binders, plastics additives, and process chemicals for various industries; and toners/toner binders, inkjet ink colorants, ink, fine polishing agents and cleaners for hard disk, and materials and process chemicals for semiconductor.
- CEO
- Yoshihiro Hasebe
- IPO
- 2004
- Employees
- 31,514
- HQ
- Tokyo, TKY, JP
Get TickerSpark's AI analysis on KAOOY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.21B
- P/E
- 23.88
- PEG
- 1.12
- P/S
- 1.84
- P/B
- 2.87
- EV/EBITDA
- 10.97
- Div Yield
- 2.18%
- Gross Margin
- 38.55%
- Op Margin
- 10.15%
- Net Margin
- 7.77%
- ROE
- 12.71%
- ROIC
- 8.61%
Latest fiscal year · YoY change
- Revenue
- $1.77T+8.7%
- Gross Profit
- $672.06B+5.3%
- Op Income
- $170.94B
- Net Income
- $125.90B+16.8%
- EPS
- $54.58+17.7%
- OCF Growth
- +3.9%
- FCF Growth
- +8.3%
- 52W High
- $8.07
- 52W Low
- $5.95
- 50D MA
- $6.78
- 200D MA
- $6.64
- Beta
- 0.18
- RSI (14)
- 61
- Avg Volume
- 204.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
The company posted a strong first quarter with higher sales, better margins, and sharply higher profit, while keeping its full-year outlook unchanged despite new U.S. tariff risks.· May 8, 2025
- Q1 net sales rose 6.6% to ¥389.9 billion, operating income was ¥31.2 billion, and net income attributable to owners of the parent rose 38.7% to ¥22.8 billion.
- Gross margin improved 0.5 points to 38%, operating margin improved to 8%, and EPS increased 38.9% to ¥49.19.
- Cosmetics is recovering, with the first-quarter operating loss limited to ¥500 million and six focus brands driving sales momentum in Japan and China.
- UV care and Curél remained key growth pillars, with management highlighting progress in building a global foundation and a 21-month streak of year-on-year market share growth for Curél.
- Management said U.S. tariff impact should be limited, estimating full-year operating income downside of up to ¥2 billion and reaffirming the fiscal 2025 forecast.
Net sales increased 6.6% year on year to ¥389.9 billion, or 6% excluding currency effects. Gross margin improved 0.5 percentage points to 38%, operating income was ¥31.2 billion, net income attributable to owners of the parent was ¥22.8 billion, up 38.7% year on year, and EPS was ¥49.19, up 38.9%. Operating income exceeded ¥30 billion for the first time in four years, and ROIC improved by 1.5 points year on year. For fiscal 2025, management maintained its full-year forecast, saying tariff-related downside should be limited and that it still expects ¥160 billion in operating income, up ¥13.4 billion, with a ¥10 billion raw material headwind offset by a ¥15 billion price adjustment and other cost actions.
Masakazu Negoro framed fiscal 2025 as a year to build a foundation for global growth toward K27, using stable earnings to fund growth investments. He said the company is steadily executing its basic strategy, with Q1 showing sales growth and operating margin expansion, and that the K27-related transformation is beginning to bear fruit. His tone was constructive but cautious, acknowledging tariff risk while emphasizing measures to keep the impact small and preserve the full-year outlook.
Management highlighted that company-wide gross margin improved to 38% from 37.4%, helped by higher-value products, cost reductions, and mix improvement rather than price actions alone. The GC business improved gross profit margin by 1.7 points, while the chemicals segment saw a 1.7-point decline from price increases; operating income in GC rose ¥8.2 billion year on year to ¥22.8 billion. For the full year, they expect operating income of ¥160 billion, including over ¥14 billion of improvement from higher earning power, a ¥10 billion raw material cost burden, ¥19 billion of SG&A increase, and a revised chemicals gross profit increase of ¥3.5 billion. They also said tariffs should be capped at ¥1.5 billion or less in GC and ¥500 million or less in chemicals.
The main concerns raised in the prepared remarks were U.S. tariffs and sustained high raw material prices. Management said tariff effects should be manageable because of local sourcing and local production, and that they are reviewing procurement, production, USMCA utilization, and pricing actions to reduce the hit. On raw materials, they said fats and oils and palm kernel oil remain elevated and may stay high through the third quarter and beyond, but they still expect the overall annual impact to be ¥10 billion and believe it can be offset.
The quarter showed broad-based operational improvement, including higher sales, margin expansion, and a big step-up in earnings, with operating income above ¥30 billion for the first time in four years. Cosmetics appears to be turning around, UV care is scaling globally, and management described K27 initiatives as starting to work in a visible way.
The company still faces pressure from tariffs, elevated fats-and-oils costs, and intense competition in overseas skin care, especially in the Americas and Europe. Cosmetics remains in recovery mode, with management only just completing inventory adjustments in China and still spending on restructuring, marketing, and global expansion initiatives.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 16.5%
- Shares Outstanding
- 2.32B
- Float Shares
- 383.74M
Held by 3 ETFs
Biggest fund positions in KAOOY by dollar value.
Our KAOOY coverage
Recent articles, reports, and earnings notes.
No research on KAOOY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KAOOY report →Kao Corporation (KAOOY) Q2 2026 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Aug 8
Kao Corporation (KAOCF) Q1 2025 Earnings Call Transcript
seekingalpha.com · May 11
Kao Corporation (KAOCF) Q4 2024 Earnings Call Transcript
seekingalpha.com · Feb 7
Kao Corporation: Regarding Shareholder Statement
businesswire.com · Dec 12
Kao Corporation (KAOCF) Q3 2024 Earnings Call Transcript
seekingalpha.com · Nov 10
Acer Announces Its First Copilot+ PC, the Swift 14 AI Laptop
https://www.prnewswire.com · May 20
Panagora Asset Management Inc. Cuts Stake in Alignment Healthcare, Inc. (NASDAQ:ALHC)
https://www.defenseworld.net · May 20
Kao Corporation (KAOCF) Q1 2024 Earnings Call Transcript
seekingalpha.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.